Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewBridge Medical Research is recruiting patients with foot ulcers due to diabetes to participate in its trial for Excellarate, an investigative product designed to stimulate the process of wound healing.
Subscribe to our email newsletter
The trial is a randomized, double-blind safety and efficacy trial in which Excellarate is topically administered once or twice over the course of the study, with a goal of complete ulcer closure at 12 weeks or earlier.
Thomas Serena, director of NewBridge Medical Research, said: “The Excellarate topical gel, using Gene Activated Matrix technology is designed to provide release of the platelet-derived growth factor BB protein, which stimulates angiogenesis (the growth of new blood vessels) and granulation tissue formation, the building blocks for a variety of wound healing processes.”